A treatment that addresses not only obesity, but also improves lipid profiles, blood pressure, glycemic control and inflammation, could potentially reduce the risk of cardiovascular disease
Abstract Background: The purpose of this study was to explore how semaglutide, a GLP-1RA, regulates serum metabolism and gut microbiota to improve obesity in mice and whether fecal microbiota transplantation (FMT) can transmit the beneficial effects of semaglutide to recipient mice
What limits the truly transformative advances from the perspective of both patient and provider
GLP-1 medications (semaglutide, liraglutide, dulaglutide) mimic a natural hormone that regulates glucose and appetite through insulin stimulation and glucagon suppression
Its crucial to follow the prescribed dosage and communicate with an experienced healthcare provider about any concerns or side effects